prader willi glp 1 Advocacy is making a difference — but safety must come first. Australia's medicines advisory body, the Pharmaceutical Benefits Advisory Committee (PBAC), has recently identified people living with Prader-Willi syndrome as a priority Prader-Willi Syndrome - MD Searchlight

The NASH-specific trial of semaglutide published in the New England Journal of Medicine in 2021 found that 59 percent of patients on semaglutide achieved resolution of NASH without worsening of fibrosis, compared to 17 percent in the placebo group

WW promotes restriction and binging cycles common in people with disordered eating patterns

Market Pressure with Major Price Cuts on Obesity & Diabetes Drugs In a bold strategic shift, Novo Nordisk has announced significant price reductions on its semaglutide-based therapies in the United States, including Wegovy a leading obesity treatment and Ozempic, a widely used antidiabetic drug

Medical Students for Size Inclusivity have created an excelled GLP-1 informed consent guide here

The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) identifies your genetic variants in GLP1R, GIPR, FTO, and MC4R pathways, which influence how your body responds to GLP-1 therapy